跳至主要内容
临床试验/TCTR20180523001
TCTR20180523001已完成未知

Topical 15% zinc oxide ointment significantly reduces the size of common warts after 4 weeks’ application: a randomized, triple-blinded, placebo-controlled trial

Ratchadaphiseksomphot Endowment Fund0 个研究点目标入组 16 人开始时间: 2018年5月23日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 70 Years(—)
性别
All

入选标准

  • Patients older than 18 years with at least 2 similar palmar warts or verruca vulgaris on either one or both hands were eligible. The wart diameter had to range between 2 to 8 millimeters, the total number of lesions had to be at least 2 but not more than 15 and they must have never been treated with any zinc preparations.

排除标准

  • Subjects who had recalcitrant warts which were defined as warts unresponsive to any treatment at least 5 times in the past 6 months, those who had known allergy to any formulation of zinc, or categorized as immunocompromised host, e.g. poorly-controlled diabetes mellitus, acquired immunodeficiency syndrome (AIDS), chronic kidney disease, or were treated with immunosuppressive agents by topical or systemic treatment, as well as pregnant or lactating women were excluded from the study.

研究者

发起方
Ratchadaphiseksomphot Endowment Fund

相似试验